Javascript must be enabled to continue!
Duchenne Muscular Dystrophy: Clinical Characteristics, Molecular Mechanisms and Management
View through CrossRef
The dystrophinopathies encompass a range of X-linked muscle disorders varying from mild to severe, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy (DCM). DMD typically manifests in early childhood and progresses rapidly, with affected children becoming wheelchair-dependent by the age of 12. Increased serum CK levels are detected in almost all DMD patients. Pathogenic variants in the DMD gene affect dystrophin expression, leading to DMD. More than four thousand pathogenic variants have been identified in the DMD gene. deletions of one or more exons are the most common variants in the DMD gene and are found in 60%-70% of patients. With current genetic methods, it is possible to elucidate the molecular etiology in approximately 95% of patients. Penetrance of DMD is complete in males. The penetrance varies in heterozygous carrier females and may depend, partly, X-chromosome inactivation (XCI) patterns. Since DMD has X-linked inheritance pattern, carrier screening should always be considered for mothers of boys with DMD. There are two important points to remember in genetic counseling for DMD. One is that 33% of DMD cases are sporadic (de novo), and the other is that the probability of germline mosaicism for DMD is 15%-20%. Sarcoglycanopathies, Emery-Dreifuss muscular dystrophy, and Barth syndrome are diseases that are included in the differential diagnosis of DMD. Since multiple systems can be affected in DMD patients, management ideally should be provided within a multidisciplinary care setting. Although corticosteroids have been shown to increase muscle strength in DMD patients and are frequently used, they are not a curative treatment. In recent years, antisense oligonucleotides and nonsense suppression therapies have emerged as variant-specific treatments. Also, several new and promising therapies have entered clinical trials or are on the horizon. In this chapter, in addition to this summary about DMD, more comprehensive information is provided.
Title: Duchenne Muscular Dystrophy: Clinical Characteristics, Molecular Mechanisms and Management
Description:
The dystrophinopathies encompass a range of X-linked muscle disorders varying from mild to severe, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy (DCM).
DMD typically manifests in early childhood and progresses rapidly, with affected children becoming wheelchair-dependent by the age of 12.
Increased serum CK levels are detected in almost all DMD patients.
Pathogenic variants in the DMD gene affect dystrophin expression, leading to DMD.
More than four thousand pathogenic variants have been identified in the DMD gene.
deletions of one or more exons are the most common variants in the DMD gene and are found in 60%-70% of patients.
With current genetic methods, it is possible to elucidate the molecular etiology in approximately 95% of patients.
Penetrance of DMD is complete in males.
The penetrance varies in heterozygous carrier females and may depend, partly, X-chromosome inactivation (XCI) patterns.
Since DMD has X-linked inheritance pattern, carrier screening should always be considered for mothers of boys with DMD.
There are two important points to remember in genetic counseling for DMD.
One is that 33% of DMD cases are sporadic (de novo), and the other is that the probability of germline mosaicism for DMD is 15%-20%.
Sarcoglycanopathies, Emery-Dreifuss muscular dystrophy, and Barth syndrome are diseases that are included in the differential diagnosis of DMD.
Since multiple systems can be affected in DMD patients, management ideally should be provided within a multidisciplinary care setting.
Although corticosteroids have been shown to increase muscle strength in DMD patients and are frequently used, they are not a curative treatment.
In recent years, antisense oligonucleotides and nonsense suppression therapies have emerged as variant-specific treatments.
Also, several new and promising therapies have entered clinical trials or are on the horizon.
In this chapter, in addition to this summary about DMD, more comprehensive information is provided.
Related Results
Challenges in developing gene therapy against Duchenne muscular dystrophy
Challenges in developing gene therapy against Duchenne muscular dystrophy
Duchenne muscular dystrophy is a progressive X-linked recessive neuromuscular disorder resulting from pathogenic mutations in the DMD gene, which codes dystrophin. It is one of the...
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin‐Deficient Hearts
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin‐Deficient Hearts
Background
Cardiomyopathy is a leading cause of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is ...
Diagnostic strategies for muscular dystrophies: a cross-sectional study
Diagnostic strategies for muscular dystrophies: a cross-sectional study
Background Muscular dystrophies are a wide heterogeneity group of neuromuscular diseases that very often constitutes a challenge for clinicians to perform an adequate diagnosis. Ma...
Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar
Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar
Abstract
Duchenne Muscular Dystrophy is a rare, X-linked neuromuscular disorder that leads to progressive muscle degeneration, loss of ambulation, and premature m...
Diagnostic strategies for muscular dystrophies: a cross-sectional study
Diagnostic strategies for muscular dystrophies: a cross-sectional study
Background:
Muscular dystrophies are a wide heterogeneity group of neuromuscular diseases that very often constitutes a challenge for clinicians to perform an ...
Role of Growth Factors and Apoptosis Proteins in Cognitive Disorder Development in Patients with Duchenne Muscular Dystrophy
Role of Growth Factors and Apoptosis Proteins in Cognitive Disorder Development in Patients with Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease; it occurs due to a mutation in the dystrophin protein gene; as a result, the protein is not synthesized an...
Dystrophie Musculaire de Duchenne: Aspects cliniques, biologiques et évolutifs à propos de cinq cas dans le service de Rhumatologie au CHU du Point G.
Dystrophie Musculaire de Duchenne: Aspects cliniques, biologiques et évolutifs à propos de cinq cas dans le service de Rhumatologie au CHU du Point G.
Résumé
La dystrophie musculaire de Duchenne (DMD) due à la non expression de la dystrophine est liée au chromosome X. Décrite au 19e siècle, est la plus courante dystrophie ...
Duchenne De Boulogne: A Pioneer in Neurology and Medical Photography
Duchenne De Boulogne: A Pioneer in Neurology and Medical Photography
ABSTRACT:Guillaume-Benjamin-Amand Duchenne was born 200 years ago in Boulogne-sur-Mer (Pas-de-Calais, France). He studied medicine in Paris and became a physician in 1831. He pract...

